raloxifene hydrochloride has been researched along with Local Neoplasm Recurrence in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (77.78) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Jordan, VC | 1 |
| Chung, SH; Lambert, PF; Spurgeon, ME | 1 |
| Lemmo, W | 1 |
| Chao, HT; Wang, PH | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Amorosi, A; Annunziata, G; Oppedisano, R; Palomba, S; Zullo, F | 1 |
| Höffken, K; Sayer, HG | 1 |
| Benatar, B; Darbhamulla, A; Watson, AJ | 1 |
| Lo, SS; Vogel, VG | 1 |
| Kurebayashi, J | 1 |
| Cuzick, J; Dixon, JM; Houssami, N | 1 |
| Aumiller, J | 1 |
| Namazi, H | 1 |
| Chao, HT; Cheng, MH; Lee, WL; Wang, PH | 1 |
| Yin, CS | 1 |
| Cohen, FJ; Glusman, J; Gradishar, W; Lu, Y; Sledge, GW; Vogel, C | 1 |
| Moore, HC | 1 |
6 review(s) available for raloxifene hydrochloride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.
Topics: Animals; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Retrospective Studies; Selective Estrogen Receptor Modulators; Students; Tamoxifen | 2021 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).
Topics: Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2004 |
[Additional effect of SERM: mammary gland].
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, LDL; Clinical Trials as Topic; Endometrial Neoplasms; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism | 2004 |
The prevention, detection, and management of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Mammaplasty; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Primary Prevention; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Sentinel Lymph Node Biopsy; Surgical Flaps; Tamoxifen; Time Factors; Trastuzumab; Ultrasonography, Mammary | 2006 |
The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
Topics: Breast Neoplasms; Clinical Trials as Topic; Contraindications; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
12 other study(ies) available for raloxifene hydrochloride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.
Topics: Animals; Biomarkers, Tumor; Cell Proliferation; Disease Models, Animal; Epithelium; Estrogen Receptor alpha; Estrogens; Female; Genitalia, Female; Humans; Mice; Mice, Transgenic; Neoplasm Recurrence, Local; Prognosis; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Uterine Cervical Neoplasms | 2014 |
Anti-Estrogen Withdrawal Effect With Raloxifene? A Case Report.
Topics: Aged; Breast Neoplasms; Capecitabine; Estrogen Antagonists; Estrogens; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2016 |
To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
Topics: Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Disease-Free Survival; Female; Humans; Incidence; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2008 |
Leuprolide acetate depot plus high-dose raloxifene hydrochloride before and after surgery for recurrent vaginal aggressive angiomyxoma: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Leuprolide; Myxoma; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Vaginal Neoplasms | 2011 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Recurrent vulval fibroids--an unusual indication for selective oestrogen receptor modulators (SERMs).
Topics: Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Leiomyoma; Middle Aged; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Treatment Outcome; Vulvar Neoplasms | 2004 |
The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2006 |
[Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?].
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |
Raloxifene can reduce giant cell tumor recurrence: a new adjuvant therapy.
Topics: Antineoplastic Agents; Bone Neoplasms; Giant Cell Tumors; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride | 2008 |
Tamoxifen: to use or not to use.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Effects of high dose raloxifene in selected patients with advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Confidence Intervals; Disease Progression; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Quality of Life; Raloxifene Hydrochloride; Receptors, Estrogen; Remission Induction; Safety; Selective Estrogen Receptor Modulators; Survival Rate; Tamoxifen | 2000 |
Managing menopause after breast cancer: balancing risks and benefits.
Topics: Adult; Alendronate; Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcitonin; Climacteric; Cohort Studies; Estrogen Antagonists; Estrogen Replacement Therapy; Female; Follow-Up Studies; Heart Diseases; Humans; Menopause; Menopause, Premature; Neoplasm Recurrence, Local; Osteoporosis; Pregnancy; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors | 2001 |